Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Eckstein

Showing results (141-150 of 263) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 12, 2020
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapyClaudia Schweizer, Philipp Schubert, Sandra Rutzner, et al.
International Journal of Molecular Sciences|November 13, 2020
High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder CancerSabine Hülsen, Eleonora Lippolis, Fulvia Ferrazzi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Cells|August 7, 2021
Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer PatientsMarkus Eckstein, Verena Lieb, Rudolf Jung, et al.
Journal of Pathology Informatics|December 23, 2024
Towards interactive AI-authoring with prototypical few-shot classifiers in histopathologyPetr Kuritcyn, Rosalie Kletzander, Sophia Eisenberg, et al.
Cancers|May 21, 2020
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node StageMarkus Eckstein, Elena Epple, Rudolf Jung, et al.
Clinical & Translational Immunology|December 20, 2021
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinomaNiklas Klümper, Philipp Schmucker, Oliver Hahn, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Cancers|September 19, 2020
Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer PatientsPaul König, Markus Eckstein, Rudolf Jung, et al.
Cells|January 20, 2021
Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant ChemotherapyHelge Taubert, Markus Eckstein, Elena Epple, et al.
Pageof 27

Showing results (141-150 of 263) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|October 12, 2020
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapyClaudia Schweizer, Philipp Schubert, Sandra Rutzner, et al.
International Journal of Molecular Sciences|November 13, 2020
High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder CancerSabine Hülsen, Eleonora Lippolis, Fulvia Ferrazzi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Cells|August 7, 2021
Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer PatientsMarkus Eckstein, Verena Lieb, Rudolf Jung, et al.
Journal of Pathology Informatics|December 23, 2024
Towards interactive AI-authoring with prototypical few-shot classifiers in histopathologyPetr Kuritcyn, Rosalie Kletzander, Sophia Eisenberg, et al.
Cancers|May 21, 2020
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node StageMarkus Eckstein, Elena Epple, Rudolf Jung, et al.
Clinical & Translational Immunology|December 20, 2021
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinomaNiklas Klümper, Philipp Schmucker, Oliver Hahn, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Cancers|September 19, 2020
Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer PatientsPaul König, Markus Eckstein, Rudolf Jung, et al.
Cells|January 20, 2021
Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant ChemotherapyHelge Taubert, Markus Eckstein, Elena Epple, et al.
Pageof 27